Surgical castration in hormone-refractory metastatic prostate cancer patients can be an alternative for medical castration - Abstract

Department of Urology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, Japan.

 

Most patients with metastatic prostate cancer are endocrinologically treated with LHRH agonist, but finally castration-refractory and hormone-refractory cancers occur. Serum testosterone levels get low to "the castration level" by LHRH agonists but may not get low enough against castration-refractory prostate cancer.

As case series, twelve patients suffering from hormone-refractory prostate cancer continuously on LHRH agonist underwent surgical castration. Additionally, one hundred and thirty-nine prostate cancer patients on LHRH agonist or surgical castration were tested for serum total testosterone levels.

Surgical castration caused decrease in serum PSA in one out of 12 hormone-refractory prostate cancer patients with PSA reduction rate 74%. Serum total testosterone levels were below the sensitivity threshold (0.05 ng/mL) in 40 of 89 (44.9%) medically castrated patients and 33 of 50 (66.0%) surgically castrated patients (P = .20).

Even hormone-refractory prostate cancer patients are candidates for surgical castration because of endocrinological, oncological, and economical reasons.

Written by:
Zaitsu M, Yamanoi M, Mikami K, Takeshima Y, Okamoto N, Imao S, Tonooka A, Takeuchi T.   Are you the author?

Reference: Adv Urol. 2012;2012:979154.
doi: 10.1155/2012/979154

PubMed Abstract
PMID: 21754927

Go "Beyond the Abstract" - Read an Article Written by the Author for UroToday.com

UroToday.com Prostate Cancer Section

 

 

email news signup